MVASI Sterile Ophthalmic Solution Lacks Assured Sterility
Edge Pharma is recalling MVASI (bevacizumab-awwb) intraocular injection syringes nationwide due to lack of assurance of sterility. The recall affects 199 syringes with code 11-2021-01@2 dated 12/15/2021.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall involving a sterile injectable pharmaceutical product. Lack of sterility assurance on a solution intended for direct intraocular injection poses a significant risk of serious infection, meeting the Severe threshold even though no reported illnesses are stated in the source.
Plain-English summary
Edge Pharma, LLC is recalling MVASI (bevacizumab-awwb), a sterile ophthalmic solution for injection supplied in single-use syringes. The product is a 3.25 mg/0.13 mL solution (25 mg/mL per syringe) intended for intraocular injection, with a dose of 1.25 mg/0.05 mL. The recall involves 199 syringes with lot code 11-2021-01@2 dated 12/15/2021 and NDC 05446-1661-13.
The recall is due to lack of assurance of sterility. Non-sterile injectable solutions can pose a serious risk of infection when administered directly into the eye.
Patients who received this product should contact their healthcare provider immediately for evaluation. Healthcare facilities should stop use of affected syringes and contact Edge Pharma, LLC for instructions on product return and replacement.
The recalled product
- Product
- MVASI, (bevacizumab-awwb), Sterile Ophthalmic Solution for Injection, 3.25mg/0.13mL (25 mg/mL) 0.13 mL per syringe, Dose: 1.25mg/0.05mL, Single Use Syringe For Intraocular Injection, Edge Pharma, LLC, 856 Hercules Dr. Colchester, VT 05446, NDC 05446-1661-13
- Manufacturer
- Edge Pharma, LLC
- Category
- Drug — Intraocular Injection
- Hazard
- lack-of-sterility
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- 11-2021-01@2 12/15/2021
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27